ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $12.50.

A number of equities analysts have recently commented on the stock. Lifesci Capital downgraded shares of ALX Oncology from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 31st. Stifel Nicolaus reissued a "hold" rating and issued a $3.00 price objective (down from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. UBS Group decreased their target price on ALX Oncology from $25.00 to $4.00 and set a "buy" rating for the company in a research report on Friday, August 16th. HC Wainwright reiterated a "buy" rating and set a $25.00 target price on shares of ALX Oncology in a report on Tuesday, August 13th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a report on Tuesday, November 12th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. CANADA LIFE ASSURANCE Co purchased a new stake in ALX Oncology during the 1st quarter worth approximately $27,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company's stock worth $39,000 after buying an additional 5,200 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of ALX Oncology in the second quarter worth $63,000. AQR Capital Management LLC raised its holdings in ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company's stock valued at $109,000 after acquiring an additional 6,080 shares in the last quarter. Finally, California State Teachers Retirement System raised its holdings in ALX Oncology by 413.8% in the first quarter. California State Teachers Retirement System now owns 22,797 shares of the company's stock valued at $254,000 after acquiring an additional 18,360 shares in the last quarter. Institutional investors and hedge funds own 97.97% of the company's stock.

ALX Oncology Trading Up 1.3 %

NASDAQ ALXO traded up $0.02 during mid-day trading on Thursday, hitting $1.51. The company's stock had a trading volume of 330,462 shares, compared to its average volume of 780,531. The firm has a market capitalization of $79.64 million, a P/E ratio of -0.51 and a beta of 1.03. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology has a 52-week low of $1.19 and a 52-week high of $17.83. The stock's fifty day simple moving average is $1.56 and its two-hundred day simple moving average is $4.64.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.